» Articles » PMID: 39028583

Human Genetic and Immunological Determinants of SARS-CoV-2 Infection and Multisystem Inflammatory Syndrome in Children

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces pneumonia and acute respiratory failure in coronavirus disease 2019 (COVID-19) patients with inborn errors of immunity to type I interferon (IFN-I). The impact of SARS-CoV-2 infection varies widely, ranging from mild respiratory symptoms to life-threatening illness and organ failure, with a higher incidence in men than in women. Approximately 3-5% of critical COVID-19 patients under 60 and a smaller percentage of elderly patients exhibit genetic defects in IFN-I production, including X-chromosome-linked TLR7 and autosomal TLR3 deficiencies. Around 15-20% of cases over 70 years old, and a smaller percentage of younger patients, present with preexisting autoantibodies neutralizing type I interferons. Additionally, innate errors affecting the control of the response to type I interferon have been associated with pediatric multisystem inflammatory syndrome (MIS-C). Several studies have described rare errors of immunity, such as XIAP deficiency, CYBB, SOCS1, OAS1/2, and RNASEL, as underlying factors in MIS-C susceptibility. However, further investigations in expanded patient cohorts are needed to validate these findings and pave the way for new genetic approaches to MIS-C. This review aims to present recent evidence from the scientific literature on genetic and immunological abnormalities predisposing individuals to critical SARS-CoV-2 infection through IFN-I. We will also discuss multisystem inflammatory syndrome in children (MIS-C). Understanding the immunological mechanisms and pathogenesis of severe COVID-19 may inform personalized patient care and population protection strategies against future serious viral infections.

References
1.
Raadsen M, Gharbharan A, Jordans C, Mykytyn A, Lamers M, van den Doel P . Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19. J Clin Immunol. 2021; 42(2):232-239. PMC: 8586830. DOI: 10.1007/s10875-021-01168-3. View

2.
Hansen K, Jorgensen S, Skouboe M, Agergaard J, Schiottz-Christensen B, Vibholm L . Examination of autoantibodies to type I interferon in patients suffering from long COVID. J Med Virol. 2023; 95(9):e29089. DOI: 10.1002/jmv.29089. View

3.
Eto S, Nukui Y, Tsumura M, Nakagama Y, Kashimada K, Mizoguchi Y . Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19. J Clin Immunol. 2022; 42(7):1360-1370. PMC: 9243824. DOI: 10.1007/s10875-022-01308-3. View

4.
Castano-Jaramillo L, Yamazaki-Nakashimada M, OFarrill-Romanillos P, Muzquiz Zermeno D, Scheffler Mendoza S, Venegas Montoya E . COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico. J Clin Immunol. 2021; 41(7):1463-1478. PMC: 8191444. DOI: 10.1007/s10875-021-01077-5. View

5.
Bastard P, Gervais A, Le Voyer T, Philippot Q, Cobat A, Rosain J . Human autoantibodies neutralizing type I IFNs: From 1981 to 2023. Immunol Rev. 2024; 322(1):98-112. PMC: 10950543. DOI: 10.1111/imr.13304. View